アメリカ膠原病の会からお知らせ

そのまま転送します。
英語でごめんなさい。

We wanted to share with you that we are working with the Arthritis Foundation (AF) to urge state pharmacy boards and other important stakeholders involved with the drug supply chain to take immediate action to ensure the availability of hydroxychloroquine (Plaquenil) and chloroquine(Aralen) for people with lupus and rheumatoid arthritis. State pharmacy boards essentially serve as the governing bodies for pharmacies and pharmacists, and play important roles in helping to ensure patient access to the medications they need. Our strategic advocacy efforts are in response to the limited availability of these medications, both of which are being studied to treat coronavirus (COVID-19). Most people with lupus now rely on hydroxychloroquine as part of their life-saving therapy.  People with lupus and their physicians across the country increasingly are reporting difficulties accessing their medications due to multiple factors including shortages of the drugs and policies that restrict their use and availability for people with lupus. The Lupus Foundation of America is committed to protecting the health of those living with lupus. It is critical that state pharmacy boards and others recognize the needs of people with lupus and take action to ensure hydroxychloroquine and chloroquine, which for decades have been used to treat the disease, continue to be available to people with lupus.